Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.07.25.220707v1?rss=1 Authors: Vandenabeele, M., Veys, L., Lemmens, S., Hadoux, X., Gelders, G., Masin, L., Serneels, L., Theunis, J., Saito, T., Saido, T., Jayapala, M., De Boever, P., De Strooper, B., Stalmans, I., van Wijngaarden, P., Moons, L., De Groef, L. Abstract: In this study, we report the results of a comprehensive phenotyping of the retina of the AppNL-G-F mouse. We demonstrate that soluble A{beta} accumulation is present in the retina of these mice early in life and progresses to A{beta} plaque formation by midlife. This rising A{beta} burden coincides with local microglia reactivity, astrogliosis, and abnormalities in retinal vein morphology. Electrophysiological recordings reveal signs of neuronal dysfunction yet no neurodegeneration was observed and visual performance outcomes were unaffected in the AppNL-G-F mouse. Furthermore, we show that hyperspectral imaging can be used to quantify retinal A{beta}, underscoring its potential as a biomarker for AD diagnosis and monitoring. These findings suggest that the AppNL-G-F retina mimics the early, preclinical stages of AD, and, together with retinal imaging techniques, offers unique opportunities for drug discovery and fundamental research into preclinical AD. Copy rights belong to original authors. Visit the link for more info